Docket No.: M0025.0292/P0292

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Satishchandra P. Patel

Application No.: Not Yet Assigned

Group Art Unit: N/A

Filed: August 1, 2003

Examiner: Not Yet Assigned

For: PHARMACEUTICAL COMPOSITIONS

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Timing of Filing of the Information Disclosure Statement:

\boxtimes	This IDS is being filed before the First Office Action.						
	This IDS is being filed after the issuance of the First Office Action but before the						
-	issuance of a Final Office Action ² .						

¹ The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement; or No item of information contained in this information disclosure statement was cited a communication from a foreign patent office in a counterpart foreign application, a to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cited application.	Applic	cation No.: Not Yet Assigned Docket No.: M0025.0292/P0292
If checked, the undersigned makes the following statement(s): Statement under 37 CFR § 1.97(e): Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of this information disclosure statement; or No item of information contained in this information disclosure statement was cited a communication from a foreign patent office in a counterpart foreign application, a to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filling of the information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the contained in this information disclosure statement was cited as the conta		
 □ Statement under 37 CFR § 1.97(e): □ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement; or No item of information contained in this information disclosure statement was cited a communication from a foreign patent office in a counterpart foreign application, a to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. □ Statement Under 37 C.F.R. § 1.704(d): □ Each item of information contained in this information disclosure statement was cited. 	Certif	fications:
Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement; or No item of information contained in this information disclosure statement was cited a communication from a foreign patent office in a counterpart foreign application, a to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cited as a counterpart foreign application, a communication contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.	If che	cked, the undersigned makes the following statement(s):
cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement; or No item of information contained in this information disclosure statement was cited a communication from a foreign patent office in a counterpart foreign application, a to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cited application.		Statement under 37 CFR § 1.97(e):
application not more than three months prior to the filing of this information disclosure statement; or No item of information contained in this information disclosure statement was cited a communication from a foreign patent office in a counterpart foreign application, a to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cited as a communication of the information disclosure statement.		Each item of information contained in this information disclosure statement was first
a communication from a foreign patent office in a counterpart foreign application, a to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cit		application not more than three months prior to the filing of this information disclosure statement; or
information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cit		a communication from a foreign patent office in a counterpart foreign application, and,
 individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cit 		to the knowledge of the undersigned after making reasonable inquiry, no item of
information disclosure statement. Statement Under 37 C.F.R. § 1.704(d): Each item of information contained in this information disclosure statement was cit		information contained in this information disclosure statement was known to any
Each item of information contained in this information disclosure statement was cit		individual designated in $\S 1.56(c)$ more than three months prior to the filing of the information disclosure statement.
		Statement Under 37 C.F.R. § 1.704(d):
in a communication from a foreign patent office in a counterpart application and th		Each item of information contained in this information disclosure statement was cited
The state of the s		in a communication from a foreign patent office in a counterpart application and this

² The IDS *must* include *either* a certification under 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p).

³ The IDS must include both a certification under 37 C.F.R. §1.97(e) and the fee set forth in 37 C.F.R. §1.17(p).

communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

Fee I	Required by 37 C.F.R. § 1.97(c)(2) or 1.97(d)(2):
	If checked, the fee of \$180.00 set forth in 37 C.F.R. §1.17(p) is attached.
Copi	es of Information:
In ac	cordance with 37 C.F.R. §1.98(a), the following are enclosed:
\boxtimes	A legible copy ⁴ of each document (or relevant portion thereof) is cited in the attached
• .	PTO/SB/08.
7 -	With respect to any information which is not in English, a concise explanation of the
	relevance, as it is presently understood by the individual designated in § 1.56(c) most
	knowledgeable about the content of the information, is attached. This concise
	explanation is provided by way of:
	A translation of the relevant portions of the non-English language
4	information⁵;
• , .	A statement explaining the relevant portions of the non-English language
	information;

⁴ A legible copy of the document is not required if (1) the information was previously cited by, or submitted to, the Office and considered by the Office in a prior U.S. application to which this application claims priority, provided that the prior application is properly identified in this IDS, and (2) the IDS submitted in the earlier application complies with 37 C.F.R. § 1.98(a) - (c). This exception does not apply to information cited in an International Application.

⁵ 37 C.F.R. §1.98(a)(3)(ii) requires that an English language translation be provided when a translation of the document, or portion thereof, "is within the possession, custody or control of, or is readily available to any individual designated in 37 C.F.R. § 1.56(c)."

Materiality:

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

⁶ The relevant portion is that portion which indicates the degree of relevance found by the foreign patent office. This may be an explanation of which portion of the of the reference is particularly relevant, to which claims it applies, or merely an "X", "Y", or "A" indication on a search report. MPEP §609 III A(3).

Application No.: Not Yet Assigned

Docket No.: M0025.0292/P0292

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: August 1, 2003

Respectfully submitted,

Edward A. Meilman

Registration No.: 24,735

DICKSTEIN SHAPIRO MORIN &

OSHINSKY LLP

1177 Avenue of the Americas, 41st Floor

New York, NY 10036-2714

(212) 835-1400

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known			
			*	Application Number	Not Yet Assigned	
INFORMATION DISCLOSURE				Filing Date	August 1, 2003	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Satishchandra P. Patel	
				Art Unit	N/A	
(Use as many sheets as necessary)			cessary)	Examiner Name	Not Yet Assigned	
heet	1	of	1	Attorney Docket Number	M0025.0292/P0292	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (if known)		Applicant of Cited Document		
	AA	4,388,307	06/14/1983	Cavanak		
	AB	5,342,625	08/30/1994	Hauer et al.		
	AC	5,759,997	06/02/1998	Cavanak		
	AD	6,057,289	05/02/2000	Mulye		
	AE	5,858,401	01/12/1999	Bhalani et al.		
	AF	US2002/0009067A1	01/24/2002	Sachs et al.		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ⁸			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^3\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.